DPP-4 Inhibitor and GPR119 Agonist Combination for Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus, such as intensive therapy with metformin, sulfonylureas, or insulin, only provide limited improvement in glycemic control and are associated with deterioration of β-cell function, leading to significant complications like cardiovascular disease, kidney damage, and vision loss, with an unmet need for drugs that offer better efficacy, safety, and disease-modifying properties.
Innovation Solution
Combining a DPP-4 inhibitor with a GPR119 agonist to enhance glycemic control, improve β-cell function, and reduce cardiovascular morbidity, while also addressing insulin resistance and metabolic disorders like obesity, through a combination therapeutic product that can be administered simultaneously, sequentially, or separately.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intensive treatment with current therapeutic drugs (metformin, sulfonylureas, or insulin) is used, then glycemic control is improved, but β-cell function deteriorates and cardiovascular complications increase
Solution Approach 1:
The patent combines two different drug classes (DPP-4 inhibitors and GPR119 agonists) into a single combination therapy. This merging approach allows the synergistic effects of both mechanisms to work together, achieving better glycemic control while reducing the harmful effects associated with monotherapy, such as β-cell function deterioration and cardiovascular complications.
Solution Approach 2:
The combination therapy represents a composite treatment approach, integrating multiple pharmacological agents with different mechanisms of action. This composite material (combination of drugs) provides a more comprehensive treatment that addresses both glycemic control and the preservation of β-cell function, thereby reducing cardiovascular risks.
2Reliability
If current therapeutic drugs are used to improve glycemic control, then blood glucose is reduced, but safety profile deteriorates with increased cardiovascular morbidity and mortality
Solution Approach 1:
By merging DPP-4 inhibitors with GPR119 agonists, the patent creates a combination therapy that maintains glycemic control effectiveness while improving the safety profile. The synergistic interaction between these two drug classes reduces cardiovascular morbidity and mortality risks compared to monotherapy.
Solution Approach 2:
The combination therapy changes the pharmacological parameters by introducing a new mechanism (GPR119 agonism) alongside the existing DPP-4 inhibition. This parameter change results in improved glycemic control with a better safety profile, specifically reducing cardiovascular complications.
3Ease of operation
If monotherapy is used, then treatment simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent merges two drug classes into a combination therapy that achieves superior therapeutic efficacy compared to monotherapy. While the treatment is no longer a single agent, the combination provides enhanced glycemic control and improved safety, making the added complexity worthwhile for achieving better clinical outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of DPP-4 inhibitors and GPR119 agonists effectively improves glycemic control, reduces glucose excursion, increases plasma GLP-1 levels, and offers a synergistic effect in treating and preventing type 2 diabetes and its complications, providing a safer and more effective therapeutic option compared to monotherapies.
Implementation Method 1
The enzyme DPP-4 (dipeptidyl peptidase IV) also known as CD26 is a serine protease known to lead to the cleavage of a dipeptide from the N-terminal end of a number of proteins having at their N-terminal end a prolin or alanin residue. Due to this property DPP-4 inhibitors interfere with the plasma level of bioactive peptides including the peptide GLP-1
Implementation Method 2
GPR119 is a Gs-protein-coupled receptor, predominantly expressed in the pancreatic beta-cells and L-cells of the gut. Activation of the receptor stimulates the cAMP signalling pathway as GLP-1R agonists do.
Implementation Method 3
Activation of the receptor stimulates the cAMP signalling pathway as GLP-1R agonists do. Therefore, an improvement of beta-cell function and beta-cell mass can be expected for an GPR119 agonist.
Data Source
AI summary
The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.